Quantifing the Circulating Epstein-Barr Virus (EBV) DNA to Monitor a Case of Aggressive Natural Killer Cell Leukemia.
10.5045/kjh.2007.42.2.167
- Author:
Seong Yoon YI
1
;
Hyo Song KIM
;
Hyun Jung JUN
;
Ji Hyun YANG
;
Young H KO
;
Chang Seok KI
;
Won Seog KIM
Author Information
1. Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. wskimsmc@smc.samsung.co.kr
- Publication Type:Case Report
- Keywords:
Aggressive natural killer cell leukemia (ANKL);
Epstein Barr virus (EBV);
Real time quantitative PCR
- MeSH:
Burkitt Lymphoma;
DNA*;
Fever;
Herpesvirus 4, Human*;
Hodgkin Disease;
Humans;
Killer Cells, Natural*;
Leukemia*;
Lymphatic Diseases;
Lymphoma;
Lymphoproliferative Disorders;
Middle Aged;
Plasma;
Polymerase Chain Reaction
- From:Korean Journal of Hematology
2007;42(2):167-171
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Epstein-Barr virus (EBV) infection is associated with various lymphoproliferative diseases, including Hodgkin lymphoma, extranodal NK/T cell lymphoma, aggressive NK cell leukemia, Burkitt lymphoma and post-transplant lymphoproliferative disorder. In the recent studies, the plasma EBV-DNA levels in patients with EBV-associated lymphoproliferative disease appeared to be correlated with the therapeutic response. Aggressive NK cell leukemia (ANKL) is a fatal disease that's characterized by high fever, lymphadenopathy, hepatosplenomegaly and frequent hemophagocytosis. No serological tumor marker for this malignancy has yet been identified for monitoring the disease and predicting the outcome. We experienced a case of aggressive natural killer cell leukemia in a 48-year-old man, and we serially monitored the plasma EBV DNA load by performing real time quantitative PCR assay. Serial measurements of the plasma EBV DNA level during therapy showed a close correlation between the clinical response and the changes in the plasma EBV DNA titers.
